About this trial
This study is a Phase II, multi-centre, single-arm, open-label study to evaluate the efficacy and safety of the combination regimen Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone in patients with newly diagnosed multiple myeloma
Patient Profile
The target population for this study are patients with newly diagnosed multiple myeloma for high dose therapy and autologous stem cell transplant. Patients will have a confirmed diagnosis of multiple myeloma, with measurable disease as per IMWG criteria.
Where’s this trial being run?
Beaumont Hospital, St James’s Hospital, University Hospital Limerick, University Hospital Waterford, Mater Misericordiae University Hospital, and Mater Private Hospital
Can I join this study / trial?
The first thing you do is to talk to your doctor and/or the cancer trials research team in your hospital. The contact details for the cancer trials research units in Ireland is here.
Why not Print this page and bring it with you. It will help your doctor and research team advise you.
Print this pageFor more detailed information
Click HereQuestions?
Here’s a list of questions you may have for your doctor or local cancer research team.
QuestionsSummary Data
| Name: | Isa-RVD |
|---|---|
| Number: | 19-34 |
| Full Title: | Isa-RVD Study: Phase II, Multi-centre, Single-Arm, Open-Label Study to evaluate the efficacy and safety of the combination regimen Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma |
| Principal Investigator: | Prof Peter O'Gorman (Chief Investigator) |
|---|---|
| Type: | In-House |
| Sponsor: | Cancer Trials Ireland |
| Recruitment Started: |
Global: April 2022 Ireland: April 2022 |
| Global Recruitment Target: | 43 |
|---|---|
| Ireland Recruitment Target: | 37 |